Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease

The majority of patients with chronic graft-versus-host disease (cGVHD) are steroid refractory (SR), creating a need for safe and effective therapies. Subcutaneous low-dose interleukin-2 (LD IL-2), which preferentially expands CD4(+) regulatory T cells (Tregs), has been evaluated in 5 clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Wobma, Holly, Kapadia, Malika, Kim, Haesook T., Alvarez-Calderon, Francesca, Baumeister, Susanne H. C., Duncan, Christine, Forrest, Suzanne, Gorfinkel, Lev, Huang, Jennifer, Lehmann, Leslie E., Li, Hojun, Schwartz, Marc, Koreth, John, Ritz, Jerome, Kean, Leslie S., Whangbo, Jennifer S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448423/
https://www.ncbi.nlm.nih.gov/pubmed/37603347
http://dx.doi.org/10.1182/bloodadvances.2023009729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448423/
https://www.ncbi.nlm.nih.gov/pubmed/37603347
http://dx.doi.org/10.1182/bloodadvances.2023009729

Ejemplares similares